Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures

NCT00060996 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00060996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00060996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures
Lead sponsor
United Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2003
Completion date
September 30, 2004
Enrollment
30
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, foot ulcers, peripheral vascular disease, rest leg pain